New Biological Insights and Recent Therapeutic Advances in the Management of Lung Cancer: A Clinical Investigator Think TankEfficacy of pemetrexed in ALK-rearranged NSCLC
0:51 minutes.
TRANSCRIPTION:
DR LOVE: You mentioned, Jeff, pemetrexed. And we’ve seen kind of stuff on and off, at least I have, about the question of whether or not it’s more effective in ALK tumors. Where do we stand on that right now? DR OXNARD: I mean, the first-line trial of crizotinib versus I think it was cis/pemetrexed had a 45% response rate or something really striking. So clearly there are greater responses with pem, and pem should be our favorite agent. If I have a resected ALK patient, I give adjuvant pem. If I have a Stage III ALK patient, I give chemoradiation with pem. There’s something about the biology of pemetrexed that is better, based on the data, in ALK patients. DR LOVE: Do you agree, Corey? DR LANGER: Absolutely. In the Phase III trial that Shaw reported in the second line, although crizotinib was clearly better than chemotherapy, pemetrexed was better than docetaxel. |